US2006057135A1PendingUtilityA1

Mucosal vascular addressins and uses thereof

52
Individually held — no corporate assignee on recordPriority: Feb 10, 1995Filed: Nov 1, 2005Published: Mar 16, 2006
Est. expiryFeb 10, 2015(expired)· nominal 20-yr term from priority
Inventors:Michael BriskinDouglas RinglerDominic PicarellaWalter Newman
A61P 29/00C07K 2319/30C07K 16/2803C07K 2317/76A61K 2039/505C07K 2319/00C07K 14/70503Y10S530/866A61P 1/00C07K 16/2839A61K 39/00
52
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to pharmaceutical compositions which comprise an antibody and/or antigen-binding fragments which have the epitopic specificity of ACT-1 monoclonal antibody.

Claims

exact text as granted — not AI-modified
1 - 100 . (canceled)  
     
     
         101 . A pharmaceutical composition, comprising an antibody or antigen-binding fragment thereof having the epitopic specificity of the ACT-1 monoclonal antibody and a physiologically acceptable vehicle or carrier, wherein said pharmaceutical composition is for treating inflammatory bowel disease in an individual.  
     
     
         102 . The pharmaceutical composition of  claim 101  wherein said antibody or antigen-binding fragment thereof is a monoclonal antibody or antigen-binding fragment thereof.  
     
     
         103 . The pharmaceutical composition of  claim 101  wherein said antibody or antigen-binding fragment thereof is the ACT-1 monoclonal antibody or an antigen-binding fragment thereof.  
     
     
         104 . The pharmaceutical composition of  claim 101  wherein said antibody or antigen-binding fragment thereof is selected from the group consisting of a chimeric antibody, an antigen-binding fragment of a chimeric antibody, a humanized antibody and an antigen-binding fragment of a humanized antibody.  
     
     
         105 . The pharmaceutical composition of  claim 101  wherein said inflammatory bowel disease is ulcerative colitis.  
     
     
         106 . The pharmaceutical composition of  claim 101  wherein said inflammatory bowel disease is Crohn's disease.  
     
     
         107 . The pharmaceutical composition of  claim 101  wherein said inflammatory bowel disease is Celiac disease, enteropathy associated with seronegative arthropathies, microscopic or collagenous colitis, eosinophilic gastroenteritis, or pouchitis.  
     
     
         108 . A pharmaceutical composition, comprising a humanized antibody or antigen-binding fragment thereof having the epitopic specificity of the ACT-1 monoclonal antibody and a physiologically acceptable vehicle or carrier, wherein said pharmaceutical composition is for treating inflammatory bowel disease in an individual.  
     
     
         109 . The pharmaceutical composition of  claim 108  wherein said inflammatory bowel disease is ulcerative colitis.  
     
     
         110 . The pharmaceutical composition of  claim 108  wherein said inflammatory bowel disease is Crohn's disease.  
     
     
         111 . The pharmaceutical composition of  claim 108  wherein said inflammatory bowel disease is Celiac disease, enteropathy associated with seronegative arthropathies, microscopic or collagenous colitis, eosinophilic gastroenteritis, or pouchitis.  
     
     
         112 . A pharmaceutical composition, comprising an effective amount of an antibody or antigen-binding fragment thereof having the epitopic specificity of the ACT-1 monoclonal antibody and a physiologically acceptable vehicle or carrier, wherein said effective amount is an amount sufficient to inhibit binding of MAdCAM to α4β7 integrin, and wherein said pharmaceutical composition is for treating inflammatory bowel disease in an individual.  
     
     
         113 . The pharmaceutical composition of  claim 112  wherein said antibody or antigen-binding fragment thereof is a monoclonal antibody or antigen-binding fragment thereof.  
     
     
         114 . The pharmaceutical composition of  claim 112  wherein said antibody or antigen-binding fragment thereof is selected from the group consisting of a chimeric antibody, an antigen-binding fragment of a chimeric antibody, a humanized antibody and an antigen-binding fragment of a humanized antibody.  
     
     
         115 . The pharmaceutical composition of  claim 112  wherein said inflammatory bowel disease is ulcerative colitis.  
     
     
         116 . The pharmaceutical composition of  claim 112  wherein said inflammatory bowel disease is Crohn's disease.  
     
     
         117 . The pharmaceutical composition of  claim 112  wherein said inflammatory bowel disease is Celiac disease, enteropathy associated with seronegative arthropathies, microscopic or collagenous colitis, eosinophilic gastroenteritis, or pouchitis.  
     
     
         118 . A pharmaceutical composition, comprising an antibody or antigen-binding fragment thereof having the epitopic specificity of the ACT-1 monoclonal antibody and a physiologically acceptable vehicle or carrier, wherein said pharmaceutical composition comprises multiple doses, and each dose comprises an effective amount of said antibody or antigen-binding fragment thereof, and wherein said pharmaceutical composition is for treating inflammatory bowel disease in an individual.  
     
     
         119 . The pharmaceutical composition of  claim 118  wherein said antibody or antigen-binding fragment thereof is a monoclonal antibody or antigen-binding fragment thereof.  
     
     
         120 . The pharmaceutical composition of  claim 118  wherein said antibody or antigen-binding fragment thereof is selected from the group consisting of a chimeric antibody, an antigen-binding fragment of a chimeric antibody, a humanized antibody and an antigen-binding fragment of a humanized antibody.  
     
     
         121 . The pharmaceutical composition of  claim 118  wherein said inflammatory bowel disease is ulcerative colitis.  
     
     
         122 . The pharmaceutical composition of  claim 118  wherein said inflammatory bowel disease is Crohn's disease.  
     
     
         123 . The pharmaceutical composition of  claim 118  wherein said inflammatory bowel disease is Celiac disease, enteropathy associated with seronegative arthropathies, microscopic or collagenous colitis, eosinophilic gastroenteritis, or pouchitis.  
     
     
         124 . A pharmaceutical composition, comprising an antibody or antigen-binding fragment thereof having the epitopic specificity of the ACT-1 monoclonal antibody and a physiologically acceptable vehicle or carrier, wherein said pharmaceutical composition is a single dose pharmaceutical composition comprising an effective amount of said antibody or antigen-binding fragment thereof, and wherein said pharmaceutical composition is for treating inflammatory bowel disease in an individual.  
     
     
         125 . The pharmaceutical composition of  claim 124  wherein said antibody or antigen-binding fragment thereof is a monoclonal antibody or antigen-binding fragment thereof.  
     
     
         126 . The pharmaceutical composition of  claim 124  wherein said antibody or antigen-binding fragment thereof is selected from the group consisting of a chimeric antibody, an antigen-binding fragment of a chimeric antibody, a humanized antibody and an antigen-binding fragment of a humanized antibody.  
     
     
         127 . The pharmaceutical composition of  claim 124  wherein said inflammatory bowel disease is ulcerative colitis.  
     
     
         128 . The pharmaceutical composition of  claim 124  wherein said inflammatory bowel disease is Crohn's disease.  
     
     
         129 . The pharmaceutical composition of  claim 124  wherein said inflammatory bowel disease is Celiac disease, enteropathy associated with seronegative arthropathies, microscopic or collagenous colitis, eosinophilic gastroenteritis, or pouchitis.

Join the waitlist — get patent alerts

Track US2006057135A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.